Member Info for sadoldgit

Agree Potnak that balances don't need to be paid until August 25. That being in full.

However, if we see below there are clauses.

The amount currently owing is greater than 10% of market cap.

Amount currently outstanding is also greater than 1 million.

'The key terms of the Facility:

· RiverFort has committed to providing an Equity Prepayment Facility of up to £5 million.

· The First Deposit of £2 million.

· Two further committed deposits of £0.3 million each on the 3-month and 6-month anniversaries of the First Deposit (the "Further Deposits")

· A fourth deposit, on the 6-month anniversary of the date of the First Deposit, of up to £1.4 million (the "Fourth Deposit") subject to the Customary Conditions (defined below) and the following trading conditions:

a) the maximum amount deposited and outstanding being not greater than 10% of the market capitalisation of the Company at the time of the deposit.

b) the maximum amount drawn and outstanding being not greater than a 15x multiple to the 10-day and 20-day Average Daily Traded Value of the Company's ordinary shares.

c) maximum amount deposited and outstanding being not greater than £1 million prior to the deposit.

· Future deposits, to the balance of up to £1 million (the "Future Deposits"), may be mutually agreed between the Company and RiverFort.

· All deposits will be subject to customary conditions precedent (including sufficient authority to allot shares and grant warrants to the Investors and disapply pre-emption rights, and no material adverse change to the Company or its '

The other option to finance is the option to on licence on less financially beneficial terms.

That does not involve share dilution.

Correct me if l am wrong BullBears.

Regards

Surfie61, the science has not changed.

I continue to add.

I have easily added several times your initial investment in the past few weeks.

That is my perogative.

That is the fact and truth.

I have never ever once advised a poster to buy.

I have suggested to one or two on here if they don't like the investment then sell.

What is wrong with that?

I have at times expressed concerns with regards to funding.

But as l am informed by certain poster here nobody including the poster, reads my posts to the end. So they will not know anyway.

You have a poster on here along with his mates over on ADVN who paint a bad picture.

These posters have no credibility but are cunning.

They will try to divide and conquer.

You chose to believe them and recommend their posts that is your perogative.

Whilst having a positive approach l have never ever made a statement that sareum will be worth 14 pounds a share, a potential if all goes well, yes.

Many times l have also stated it may be a bumpy ride. That means up and down. We sit at a down at the moment. Sentiment is important as you must realise.

So whilst you are concerned about your current losses as to some extent all of us are why do you feed and support those that have an agenda to drive this SP as low as they can?

Expect the best but be prepared for the worst.

We normally end up with what we genuinely expect.

I am expecting the best, and you whether you know it or not are expecting the worse.

Try filling your mind with positives. I take this as an opportunity to add significantly at a low price.

You see this not as an opportunity but impending doom pushed into you by the constant repetitive

predictors of doom and gloom.

The ' listen to me person' who will try to undermine any poster with a slightly positive attitude.

I see successs where others see failure.

Yes l see risk and yes l see reward.

Regards and have a good day.

It is not good to have a weak mind.

So by that very statement either the individual is stating false information for whatever reason, or you like him are ignorant as to what l have posted

Surfie61 l have been adding for weeks on a nigh daily basis. Smallish 15k shares yesterday at 16.13 hrs was my last addittion.

Just over doubled my holding here.

The price is ridiculously low for what we have in the pipeline.

That is my belief and why l continue to buy. A similar belief to others.

Regards

Good morning Potnak.

I am pretty sure that Tim and Co have a good idea how phase 1a is going.

However, they cannot release any info regarding until all date is analysed.

Follow ups on trial volunteers will add some time.

Tim an Co can be confident of good results, that is about as close as you will get in an indication.

Pleased l have added considerably over past week or so.

Regards

You make sense there xviolet.

They could raise a placing if indeed it is needed to complete 1a.

Personally l think they have enough for end of 1a, but as Damion suggested would require the money for the trial so they can recuperate the 1.6 million tax credits at mid July.

Should they reach a stage whereby all data is recieved and proves satisfactory then a placing to a higher value maybe required unless a deal is struck with an on licensee

Regards

No, l was not talking to you Hood.

Looks like the only thing stupid is you.

What on earth possessed you to too invest in the first place?

Don't tell me you are invested and been invested for years.

TBC123 looks like we have at least a 3 way umbilical cord here. You the Hood and a couple of Bristols over on ADVN.

Post something of substance.

Regards

A mere 2% of Psoriasis market would suffice although in reality likely to be much higher.

https://finance.yahoo.com/news/psoriasis-treatment-market-size-surpass-131700867.html#:~:text=psoriasis%20treatment%20market%3F-,The%20global%20psoriasis%20treatment%20market%20size%20was%20valued%20at%20USD,8.8%25%20during%20the%20forecast%20period.

Regards

Early Jak inhibitors lacked selectivity. Yes they would have efficacy but at the same time off target effects caused by lack of selectivity.

No such thing as one size fits all.

Later generation inhibitors have greater selectivity and now we have an Allosteric inhibitor that is so selective its a ability to treat certain Indications is somewhat restricted due to lack of efficacy.

It does appear than in an effort caused by sheer greed by BMS to obtain this all singing and dancing inhibitor it will be out classed and bettered in many Indications.

BMS must have been extremely disappointed with the UC data results. Nowhere near achieving the endpoints.

Regarding Psoriasis, we are not the only pharma that believe they can better Deucravacitinib.

Of the firm belief we can better the Deucra PASI 75 score in around 12 weeks.

What a lovely report on Deucravacitinib.

https://www.dermatologytimes.com/view/deucravacitinib-a-year-in-review

From late 2014.

Interleukin-22 (IL-22) is an IL-10 family cytokine that was recently discovered to be released by T helper 17 (Th17) cells, Th22 cells, etc. Recently, there is emerging evidence that IL-22 is involved in the development and pathogenesis of psoriasis. For instance, IL-22 can inhibit keratinocyte terminal differentiation and can induce psoriasis-like epidermis alterations; serum IL-22 levels were correlated with the disease severity of psoriasis patients, and IL-22 mRNA was positively expressed in the psoriatic skin lesions, but negatively expressed in the normal controls. All these findings suggest that IL-22 may be implicated in psoriasis; therapeutics targeting IL-22 may have promise as a potential therapeutic target for treating psoriasis. In the present review, we summarize recent advances on the role of IL-22 in the pathogenesis and treatment of psoriasis.'

From the this post and the previous post we can deduce that there is no reason as to why the SDC compound cannot out perform Deucravacitinib.

Allosteric Tyk2 cannot inhibit IL-22. Keratinocyte production therefore cannot be inhibited by allosteric Tyk2.

One thing for sure is, it is not of the benefit of BMS to have such a promising potential of a commercialised Tyk2 Jak1 inhibitor such as SAR-20347.

Regards

There is no reason why SAR20347 cannot out perform Deucravacitinib.

'20347

. Both Tyk2 mutant mice and mice treated with SAR-20347 showed significant reduction of IL-6 and IL-17 in imiquimod-induced skin lesions, but only SAR-20347-treated mice presented reduced levels of IL-23, decreased keratinocyte proliferation and improved clinical score [22]. In addition, SAR-20347-treated mice manifested lower IL-17 gene expression compared to Tyk2 mutant mice [22]. In this model, Works et al. demonstrated that SAR-20347 treated mice showed an almost complete loss of IL-22 gene expression in skin lesions, and they postulate that SAR-20347 would impair the ability of Th17 and γδ cells to induce IL-22 [22]. IL-22 is required for development of autoreactive Th17 cells [77,78]. However, not only IL-22 production was impaired, since IL-22 signaling was also affected in vitro in a human colonic cell line, and STAT3 phosphorylation dependent of IL-22 was completely blocked [22].'

In addition

'Blocking both Tyk2 and Jak1 in this study was more effective than inhibition of Tyk2 alone at reducing psoriasis-like disease severity, keratinocyte proliferation, as well as IL-23, IL-17, IL-6, IL-22, and antimicrobial peptide gene expression, and the authors postulate that targeting a combination of Jak1 and Tyk2 using an orally available inhibitor may be a viable approach for treating psoriasis, but currently there are no ongoing or completed clinical trials for SAR-20347 [22].'

There are trials ongoing now! The above report from early 2023.

Now those that bother to read my posts will know the importance l believe in Jak pairing.

Jak1 and Jak2 in particular

The all important interleukin 10.

4 subunits of IL-10

2 of which are Jak1 and 2 of which are Tyk2.

Deucravacitinib the allosteric inhibitor does not interact with either Jak1 or Jak2 in the human body.

20347 is not an allosteric inhibitor.

Good morning HbD,

I have pointed out previously the costs associated with current immunotherapy and immuno oncology.

Generally around 100k dollars a year,

Many of the treatments have a 2 year treatment plan.

At the same time we have stem cell treatments than run into 7 figure sums.

Regards

Gunner68, why do we need tox studies on 1802 when 1801 is going through phase 1a trial and we await the results?

My take on it is RF will not be selling Sareum shares today, indeed the 75k which showed as a sell did not materialise.

Suspension is temporary,

Regards

A good link HbD.

I am of the belief we can be better than Deucracitinib with regards to efficacy and would suggest we can obtain a better PASI score of 75 by the end of a twelve week period. This was a target by BMS but did not achieve.

As a negative poster put here when l stated the advantages of dual inhibition in this indication his reply.

I can see them all sitting around the table and saying ' well why didn't we think of this,'

Sarcasm!

But they did not think of this at the time.

They cannot change what they have done, all the can do is sit back and watch the later advanced dual inhibition Tyk2 Jak1 inhibitors with potential greater efficacy knock Deucracitinib from the top of its lofty perch.

Again by having the dual approach there is plenty of hypothesis to support this as well as substantial evidence in preclinical studies

All the more important to obtain the phase1 data results, interpretation of leading to phase 1b trial should the finance issues be resolved.

Regards

IL-10.

https://www.thermofisher.com/uk/en/home/life-science/antibodies/antibodies-learning-center/antibodies-resource-library/cell-signaling-pathways/il-10-pathway.html

HbD you have certainly selected the most pertinent and applicable info regarding 1801.

Regards

Good morning again HbD,

Indications and potential with regards to Tyk2 and Jak1 have been well documented.

Pleased you have read and given a very credible response.

As you will realise the potential worth here is considerable.

There exists plenty of room here for 1801 to surpass Deucravacitinib in some Indications and Psoriasis being one if them

We must also take into account that very importantly inter leuken 10 that is of great relevance with regards to the auto immune system consists of 4 sub units of which 2 are controlled by Jak1, and 2 are controlled by Tyk2

Also of relevance is the degree of selectivity of Jak1 over Jak2 and Jak3, of which we are from memory 4 or five fold selective over.

If we now take the extremely high purity of our SdC compounds that use our patent protected crystallisation of a compound. ( yes we have had the naysayers claim that this is not new and indeed they are correct) However it has its importance in ensuring top patent protection guarding its manufacture.

The final icing on the cake is the administration via the oral route through capsule formulation which basisicslly removes the possibilities of the compound or part compound passing through the intestinal tract unabsorbed.

Great for dosing precision.

LADMET.

Regards

Regards and have a great day.